Cardiff Oncology
CRDF

$2.34

1.06%

Market Cap: 105M

About: Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Employees: 32

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,335% more call options, than puts

Call options by funds: $4.67M | Put options by funds: $325K

469% more capital invested

Capital invested by funds: $7.84M [Q4 2023] → $44.6M (+$36.7M) [Q1 2024]

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

38% more funds holding

Funds holding: 55 [Q4 2023] → 76 (+21) [Q1 2024]

6.87% more ownership

Funds ownership: 11.85% [Q4 2023] → 18.72% (+6.87%) [Q1 2024]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$7

199%

upside

Avg. target

$11.67

399%

upside

High target

$14

498%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	498%upside $14	Buy Reiterated	6 May 2024
HC Wainwright & Co. Raghuram Selvaraju	498%upside $14	Buy Maintained	6 Mar 2024
Piper Sandler Joseph Catanzaro	199%upside $7	Overweight Maintained	1 Mar 2024

See Analyst Rankings

Financial journalist opinion

Cardiff Oncology to Present at the Jefferies Healthcare Conference

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival. Ongoing Phase 2 trials for Onvansertib in various cancers include collaborations with Pfizer and other prestigious institutions.

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology to Present at Upcoming Investor Conferences in May

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.

Cardiff Oncology to Present at Upcoming Investor Conferences in May

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains.

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q1 2024 Results Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Mark Frahm - TD Cowen Joseph Catanzaro - Piper Sandler Andy Hsieh - William Blair Operator Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Zacks Investment Research

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program -

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump.

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC – Therapeutic areas outside of RAS-mutated mCRC – In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status – – In SCLC and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors – SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the presentation of five abstracts at the American Association for Cancer Research (AACR), taking place from April 5-10, 2024, in San Diego, California. In combination, the abstracts underscore the significant potential of the company's lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

See News Rankings